• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cortexyme, Inc. (Amendment)

    4/27/21 11:35:58 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRTX alert in real time by email
    SC 13G/A 1 d175546dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Amendment No. 2)

    Under the Securities Exchange Act of 1934

     

     

    CORTEXYME, INC.

    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.001

    (Title of Class of Securities)

    22053A 107

    (CUSIP Number)

    DECEMBER 31, 2020

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 22053A107

       Page 2 of 5 Pages

     

      1.    

      Name of Reporting Persons

     

      David A. Lamond

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person With:

       5.     

      Sole Voting Power

     

      2,048,938

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      2,048,938

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,048,938

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      6.9%

    12.  

      Type of Reporting Person (See Instructions)

     

      IN


    CUSIP No. 22053A107

       Page 3 of 5 Pages

     

     

    Item 1(a).

    Name of Issuer.

    Cortexyme, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices.

    269 East Grand Avenue, South San Francisco, CA 94080

     

    Item 2(a).

    Name of Person Filing.

    David A. Lamond

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence.

    c/o Cortexyme, Inc., 269 East Grand Avenue, South San Francisco, CA 94080

     

    Item 2(c).

    Citizenship.

    United States of America

     

    Item 2(d).

    Title of Class of Securities.

    Common Stock, par value $0.001

     

    Item 2(e).

    CUSIP Number.

    22053A107

     

    Item 3.

    Not applicable.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    2,048,938 shares of common stock. This amount includes: (i) 301,829 shares of common stock held of record by David A. Lamond and (ii) 1,747,109 shares of common stock held of record by Blue Devil Trust dated 12/03/2010. Mr. Lamond is the trustee of Blue Devil Trust 12/03/2010 and holds sole voting and dispositive power with respect to the shares held of record by Blue Devil Trust dated 12/03/2010.

    (b) Percent of class:

    The common stock represents approximately 6.9% of the Issuer’s common stock, based on 29,552,123 issued and outstanding shares of common stock of the Issuer as of February 24, 2021 as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021.

    (c) Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote: 2,048,938

     

      (ii)

    Shared power to vote or to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of: 2,048,938

     

      (iv)

    Shared power to dispose or to direct the disposition of: 0

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent of Another Person.

    Not applicable.


    CUSIP No. 22053A107

       Page 4 of 5 Pages

     

    Item 7.

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not applicable.


    CUSIP No. 22053A107

       Page 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 27, 2021.

     

    By:  

    /s/ David A. Lamond

      David A. Lamond
    Get the next $CRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRTX

    DatePrice TargetRatingAnalyst
    3/9/2022$30.00 → $15.00Buy
    HC Wainwright & Co.
    1/28/2022$75.00 → $12.00Buy → Hold
    Canaccord Genuity
    1/28/2022Buy → Hold
    Canaccord Genuity
    1/27/2022Mkt Outperform → Mkt Perform
    JMP Securities
    10/27/2021Neutral → Underperform
    B of A Securities
    10/27/2021$58.00 → $15.00Neutral → Underperform
    BofA Securities
    10/27/2021$200.00 → $30.00Buy
    HC Wainwright & Co.
    9/16/2021$75.00 → $150.00Buy
    Canaccord Genuity
    More analyst ratings

    $CRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

    New ticker symbol (NASDAQ:QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (NASDAQ:CRTX) today announced that the company's planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics' go-forward growth strategy and development pipeline plans. Additionally, the company's ticker symbol on the Nasdaq Global Select Market is expected change to "QNCX" effective at the open of market trading on Monday, August 1, 2022. The company's common stock will continue to trade under the ticker sym

    7/27/22 8:01:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

    Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company's lysine gingipain inhibitor in development for the treatment of Alzheimer's disease and indications with disease pathology associated with the keystone pathogen P. gingivalis. The study was a randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, an

    7/27/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company's 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after oral treatment. COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition. 3CLpro, or Mpro, is a validated antiviral drug target shown to be essential in viral r

    6/21/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    SEC Filings

    View All

    Cortexyme Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    12/16/22 4:04:17 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Cortexyme Inc.

    10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

    11/9/22 4:17:03 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Inc. filed SEC Form 8-K: Leadership Update

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    9/30/22 5:08:03 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Cortexyme with a new price target

    HC Wainwright & Co. reiterated coverage of Cortexyme with a rating of Buy and set a new price target of $15.00 from $30.00 previously

    3/9/22 6:45:17 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Cortexyme from Buy to Hold and set a new price target of $12.00 from $75.00 previously

    1/28/22 7:19:09 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme downgraded by Canaccord Genuity

    Canaccord Genuity downgraded Cortexyme from Buy to Hold

    1/28/22 6:06:43 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Monohon Ted covered exercise/tax liability with 1,640 shares, decreasing direct ownership by 5% to 29,311 units to cover taxes

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    12/7/22 5:37:47 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Monohon Ted covered exercise/tax liability with 1,520 shares, decreasing direct ownership by 5% to 30,951 units to cover taxes

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    9/8/22 5:58:12 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Monohon Ted

    4 - Cortexyme, Inc. (0001662774) (Issuer)

    7/1/22 5:03:16 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Cortexyme Appoints June Bray to its Board of Directors

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company's Board of Directors. "We are very pleased to welcome a seasoned pharmaceutical and global regulatory expert of June Bray's caliber to our Board of Directors," said David Lamond, chairperson of Cortexyme's Board of Directors. "With more than four decades of pharmaceutical industry experience, we look forward to her valuable contribution and perspective across multiple therapeutic areas." "I am excited to join Cortexyme's B

    6/13/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Appoints Dr. Philip Low to Its Board of Directors

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company's Board of Directors. "In conjunction with today's acquisition of Novosteo, we are very pleased to welcome a distinguished researcher, innovator, and entrepreneur of Dr. Philip Low's caliber to our Board of Directors," said David Lamond, chairman of Cortexyme's Board of Directors. "His vast expertise across targeted drug discovery, prolific research abilities, and pro

    5/20/22 8:01:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Announces Agreement to Acquire Novosteo

    Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company Planning corporate name change to Quince Therapeutics to reflect broadening of therapeutic pipeline Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skelet

    5/10/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Financials

    Live finance-specific insights

    View All

    Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer's Disease Progression

    In overall population, co-primary endpoints of ADAS-Cog11 and ADCS-ADL were not met Pre-specified subgroups representing up to half of the participants based on P. gingivalis infection level showed approximately 50% slowing of cognitive decline Clinical data validated upstream mechanism of action and benefits of targeting P. gingivalis Additional top-line GAIN Trial results to be presented at CTAD 2021 on November 11th Cortexyme to host investor conference call today Tuesday, October 26th at 4:30 p.m. Eastern Time Cortexyme, Inc. (NASDAQ:CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat

    10/26/21 4:01:00 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)

    SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)

    7/8/22 12:56:11 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)

    SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)

    2/11/22 2:48:42 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)

    SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)

    2/11/22 12:22:48 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care